Distinguished in Rhizomelic Pseudopolyarthritis

Emmanuelle Dernis

Le Mans, FR 
Distinguished in Rhizomelic Pseudopolyarthritis
Le Mans, FR 
OverviewLocationsClinical Research

Overview

Emmanuelle Dernis practices in Le Mans, France. Ms. Dernis is rated as a Distinguished expert by MediFind in the treatment of Rhizomelic Pseudopolyarthritis. Her top areas of expertise are Arthritis, Rheumatoid Arthritis (RA), Polymyalgia Rheumatica, Rhizomelic Pseudopolyarthritis, and Synovectomy.

Her clinical research consists of co-authoring 79 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 5 articles and participated in 1 clinical trial in the study of Rhizomelic Pseudopolyarthritis.

Gender
Female

Locations

Le Mans, France
Other Locations
Besancon, France
Caen, France
Tours, France
Infirmerie Protestante de Lyon, Caluire et Cuire
Lyon, France
Morlaix, France
CHU d'Angers
Angers, 49100, France
CHU Nantes
Nantes, France
CHU Clermont Ferrand
Clermont-ferrand, France
CHR d'Orléans
Orleans, France
194, Avenue Rubillard, 72000, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: July 22, 2025
Intervention Type: Drug
Study Drugs: Baricitinib, TNF Inhibitor
Study Phase: Phase 4
Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis
Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: November 18, 2024
Intervention Type: Drug, Biological
Study Drugs: Secukinumab, TNF blocker, Blood specimen
Study Phase: Phase 4
Interest of Continuous Non-Steroidal Anti-Inflammatory Drug Treatment in Ankylosing Spondylitis Patients Treated by Anti-TNF Therapy in the Prevention of Radiographic Outcomes
Interest of Continuous Non-Steroidal Anti-Inflammatory Drug Treatment in Ankylosing Spondylitis Patients Treated by Anti-TNF Therapy in the Prevention of Radiographic Outcomes
Enrollment Status: Completed
Publish Date: July 16, 2024
Intervention Type: Drug
Study Drugs: NSAIDs, anti-TNF
Study Phase: Phase 3
Randomized Placebo-controlled Trial Comparing Methotrexate vs. Methotrexate/Metformin Association in Rheumatoid Arthritis Patients
Randomized Placebo-controlled Trial Comparing Methotrexate vs. Methotrexate/Metformin Association in Rheumatoid Arthritis Patients
Enrollment Status: Active_not_recruiting
Publish Date: June 21, 2024
Intervention Type: Other, Drug
Study Drugs: Metformin, Methotrexate
Study Phase: Phase 2
Smart Marker Annunciating Response to Rheumatologic Treatments SMART²T
Smart Marker Annunciating Response to Rheumatologic Treatments SMART²T
Enrollment Status: Completed
Publish Date: January 18, 2024
Intervention Type: Device
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Tofacitinib in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic DMARDs or Biologic DMARDs
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Tofacitinib in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic DMARDs or Biologic DMARDs
Enrollment Status: Terminated
Publish Date: November 30, 2023
Intervention Type: Drug, Biological
Study Drugs: Otilimab, Tofacitinib, csDMARDs
Study Phase: Phase 3
Development and Validation of a Simple Diagnostic Tool Predictive of the Aseptic Character of Joint Effusion
Development and Validation of a Simple Diagnostic Tool Predictive of the Aseptic Character of Joint Effusion
Enrollment Status: Completed
Publish Date: March 09, 2022
Intervention Type: Procedure
Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis
Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: August 09, 2021
Intervention Type: Drug
Study Phase: Phase 4
Relationship Between T LYmphocytes Depletion and Clinical Response to RITUXimab in Rheumatoid Arthritis (LYRITUX)
Relationship Between T LYmphocytes Depletion and Clinical Response to RITUXimab in Rheumatoid Arthritis (LYRITUX)
Enrollment Status: Completed
Publish Date: May 06, 2021
Intervention Type: Drug
Study Drug: Rituximab
Study Phase: Phase 3
Safety and Efficacy of tocilizuMAb Versus Placebo in Polymyalgia rHeumatica With glucocORticoid dEpendence SEMAPHORE
Safety and Efficacy of tocilizuMAb Versus Placebo in Polymyalgia rHeumatica With glucocORticoid dEpendence SEMAPHORE
Enrollment Status: Completed
Publish Date: December 04, 2020
Intervention Type: Drug
Study Phase: Phase 3
Lead Time of the Methotrexate Establishment and Vaccinal Protection Against the Pneumococcal Agent in Patients Affected With Rheumatoid Polyarthritis
Lead Time of the Methotrexate Establishment and Vaccinal Protection Against the Pneumococcal Agent in Patients Affected With Rheumatoid Polyarthritis
Enrollment Status: Completed
Publish Date: August 03, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 3
Treat to Target Trial in Axial Spondylo Arthritis : The TICOSPA (Tight Control in Spondyloarthritis)
Treat to Target Trial in Axial Spondylo Arthritis : The TICOSPA (Tight Control in Spondyloarthritis)
Enrollment Status: Completed
Publish Date: September 27, 2019
Intervention Type: Other
View 11 Less Clinical Trials

79 Total Publications

When generative artificial intelligence answers to Google Trends about spondyloarthritis: what does a French expert panel think about it?
When generative artificial intelligence answers to Google Trends about spondyloarthritis: what does a French expert panel think about it?
Journal: RMD open
Published: June 06, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Dernis's expertise for a condition
ConditionClose
    View All 30 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile